EESMO Open3/17/2026479P Microbiota-modifying medications and gut microbiome features in neoadjuvant immunotherapy for resectable NSCLC: A post-hoc analysis of the LCMC3 trialA. Cortellini·Kazuki Takada·L. Brunetti·M. Shimokawa·J.T. Ferri·D.J. Pinato·M.R. Conroy·F.Y. Shaikh·C. Sears·J. Naidoo·V. Santo·L. Wang·M. Russano·S. Takamori·J. WhiteRead at ESMO OpenTagsGut microbiota and healthMolecular Biology
